- R&D
Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...Developments in RNA Research Win Nobel Prizes for the Second Consecutive Year
After last year’s Nobel Prize in Physiology or Medicine was awarded to Drew Weissman and Katalin Karikó for their work on mRNA vaccines, which...
- Clinical
Sling Therapeutics Challenges Tepezza in Thyroid Eye Disease Treatment
Sling Therapeutics has achieved a milestone in the development of its oral treatment for thyroid eye disease (TED), linsitinib. In a recent phase 2b/3...J&J’s Lung Cancer Combo Outperforms Tagrisso in Survival Rates
Johnson & Johnson has achieved a breakthrough in the treatment of non-small cell lung cancer (NSCLC), with its combination therapy of Rybrevant and Lazcluze...Blueprint Terminates Clinical-Stage CDK2 Inhibitor Program but Continues Breast Cancer Research
Blueprint Medicines has announced the termination of its clinical-stage CDK2 inhibitor program, including the development of BLU-222, but reaffirmed its commitment to advancing preclinical...Sanofi and SK bioscience advance their 21-Valent vaccine to Phase 3
Sanofi has announced a new step forward in its collaboration with SK bioscience, providing a €50 million ($52 million) upfront payment to propel their...
- Commercial
Regenxbio And Nippon Sinyaku Pen $810M Gene Therapy Agreement
Regenxbio has struck a strategic partnership valued at $810 million with Japan's Nippon Shinyaku to promote gene treatments aimed at the uncommon metabolic condition...Umoja Biopharma Secures $100 Million Series C Funding for Cell Therapy Advancements
Umoja Biopharma has successfully closed a $100 million Series C funding round, marking a step forward for the company’s efforts to advance innovative cell...Tune Therapeutics Raises Whopping $175M to Bring Epigenetic Drug Into Clinic
Investors are clearly in no doubt over the functionality of Tune Therapeutics’ epigenetic silencing drug, providing the biotech with an astounding $175 million in...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
- R&D
Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...Developments in RNA Research Win Nobel Prizes for the Second Consecutive Year
After last year’s Nobel Prize in Physiology or Medicine was awarded to Drew Weissman and Katalin Karikó for their work on mRNA vaccines, which...
- Clinical
Sling Therapeutics Challenges Tepezza in Thyroid Eye Disease Treatment
Sling Therapeutics has achieved a milestone in the development of its oral treatment for thyroid eye disease (TED), linsitinib. In a recent phase 2b/3...J&J’s Lung Cancer Combo Outperforms Tagrisso in Survival Rates
Johnson & Johnson has achieved a breakthrough in the treatment of non-small cell lung cancer (NSCLC), with its combination therapy of Rybrevant and Lazcluze...Blueprint Terminates Clinical-Stage CDK2 Inhibitor Program but Continues Breast Cancer Research
Blueprint Medicines has announced the termination of its clinical-stage CDK2 inhibitor program, including the development of BLU-222, but reaffirmed its commitment to advancing preclinical...Sanofi and SK bioscience advance their 21-Valent vaccine to Phase 3
Sanofi has announced a new step forward in its collaboration with SK bioscience, providing a €50 million ($52 million) upfront payment to propel their...
- Commercial
Regenxbio And Nippon Sinyaku Pen $810M Gene Therapy Agreement
Regenxbio has struck a strategic partnership valued at $810 million with Japan's Nippon Shinyaku to promote gene treatments aimed at the uncommon metabolic condition...Umoja Biopharma Secures $100 Million Series C Funding for Cell Therapy Advancements
Umoja Biopharma has successfully closed a $100 million Series C funding round, marking a step forward for the company’s efforts to advance innovative cell...Tune Therapeutics Raises Whopping $175M to Bring Epigenetic Drug Into Clinic
Investors are clearly in no doubt over the functionality of Tune Therapeutics’ epigenetic silencing drug, providing the biotech with an astounding $175 million in...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
Editor Picks
Lyme disease vaccine by Valneva up for final stage clinical trials
Phase III commencement of Lyme disease vaccine was announced by Valneva and...
FDA allows Priority Review for ALS drug after accepting New Drug Application
According to Ionis’ announcement, the U.S. FDA accepted an NDA (New Drug...
Bad News for AbbVie as Emraclidine Fails to Perform in Trials
AbbVie saw its valuation drop by around $40 billion following disappointing results from two...
Must Read
Regenxbio And Nippon Sinyaku Pen $810M Gene Therapy Agreement
Regenxbio has struck a strategic partnership valued at $810 million with Japan's Nippon Shinyaku...
Sling Therapeutics Challenges Tepezza in Thyroid Eye Disease Treatment
Sling Therapeutics has achieved a milestone in the development of its oral treatment for...
Umoja Biopharma Secures $100 Million Series C Funding for Cell Therapy Advancements
Umoja Biopharma has successfully closed a $100 million Series C funding round, marking a...
About Us
Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.
Contact us: reachout(at)lifescivoice.com